Dunja Ana Vekic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dunja Ana Vekic has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- John Walter Frew
Department of Dermatology Liverpool Hospital Liverpool New South Wales Australia
6 shared publications Jane Woods
Department of Dermatology, Liverpool Hospital, Sydney, Australia
5 shared publicationsGeoffrey D Cains
Dermatology Research Group, Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia
3 shared publicationsGeoffrey D. Cains
Department of Dermatology, Liverpool Hospital, Liverpool, Australia; University of New South Wales, Sydney, Australia; Ingham Institute of Applied Medical Research, Liverpool, Australia
3 shared publicationsGeoffrey David Cains
Ingham Institute for Applied Medical Research, Sydney, NSW, Australia
2 shared publications- Alicia Oshlack
Peter MacCallum Cancer Centre, Parkville, Australia
1 shared publication
Latest Publications
- 23 January 2018
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 59 (4) , 261-266
Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 2
Hidradenitis suppurativa is a chronic, painful, autoinflammatory condition resulting in nodules, abscesses and sinus tracts. We present an evidence‐based review providing new understanding of the pathogenesis of hidradenitis suppurativa and associated comorbidities. By the nature of their speciality, dermatologists are uniquely positioned to investigate and treat patients.
- 23 January 2018
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 59 (4) , 261-266
Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 2
Hidradenitis suppurativa is a chronic, painful, autoinflammatory condition resulting in nodules, abscesses and sinus tracts. We present an evidence‐based review providing new understanding of the pathogenesis of hidradenitis suppurativa and associated comorbidities. By the nature of their speciality, dermatologists are uniquely positioned to investigate and treat patients.
- 21 January 2018
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 59 (4) , 267-277
Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1
Hidradenitis suppurativa is a chronic, painful, autoinflammatory condition resulting in nodules, abscesses and sinus tracts. We present an evidence‐based review providing new understanding of the pathogenesis of hidradenitis suppurativa and associated comorbidities. By the nature of their speciality, dermatologists are uniquely positioned to investigate and treat patients with this condition. Data collected from a subspecialty hidradenitis suppurativa clinic (N = 106) and experiences thereof are discussed in this review.
- 21 January 2018
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 59 (4) , 267-277
Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1
Hidradenitis suppurativa is a chronic, painful, autoinflammatory condition resulting in nodules, abscesses and sinus tracts. We present an evidence‐based review providing new understanding of the pathogenesis of hidradenitis suppurativa and associated comorbidities. By the nature of their speciality, dermatologists are uniquely positioned to investigate and treat patients with this condition. Data collected from a subspecialty hidradenitis suppurativa clinic (N = 106) and experiences thereof are discussed in this review.
- 1 January 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (1) , 217-219.e2
Drug-associated hidradenitis suppurativa: A systematic review of case reports
- 1 January 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (1) , 217-219.e2
Drug-associated hidradenitis suppurativa: A systematic review of case reports
- 29 December 2017
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 59 (3) , e243-e244
Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life‐changing drug or does lifestyle change the drug?
- 29 December 2017
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 59 (3) , e243-e244
Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life‐changing drug or does lifestyle change the drug?
- 20 September 2017
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 177 (4) , 987-998
A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a severe chronic inflammatory disorder characterized by recurrent painful deep-seated nodules with a predilection to the apocrine-bearing areas of skin. A minority of cases of HS are due to mutations in the γ-secretase complex. Contention exists surrounding the pathogenicity of sequence variants and their effects upon Notch signalling. This systematic review was registered with PROSPERO (CRD42016041425) and was conducted in line with the PRISMA statement. Eligibility criteria for this review included published case reports, case series and reviews that identified sequence variants or protein or functional studies from patients with HS. Sixty-two articles were identified reporting a total of 41 sequence variants – heterozygous missense (nine), splice site (nine), insertion resulting in frameshift (one), premature termination codon (19) and promoter region PSTPIP1 (three) – with 18 associated protein or functional studies. The American College of Medical Genetics and Genomics standards and guidelines on the interpretation of sequence variants were applied to each identified variant to assess evidence for pathogenicity. Twenty-three variants were assessed as likely pathogenic, 17 of uncertain significance and one benign. The large number of variants of ‘uncertain significance’ is largely due to the variable number of functional studies. Four studies used Notch as a proxy for γ-secretase function, with conclusions of nonpathogenicity based on the assumption of Notch signalling as the sole pathogenic process. The role of Notch-independent signalling mechanisms requires further research. Limitations to this study include identification of variants of Mendelian inheritance and not complex polygenic traits.
- 20 September 2017
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 177 (4) , 987-998
A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a severe chronic inflammatory disorder characterized by recurrent painful deep-seated nodules with a predilection to the apocrine-bearing areas of skin. A minority of cases of HS are due to mutations in the γ-secretase complex. Contention exists surrounding the pathogenicity of sequence variants and their effects upon Notch signalling. This systematic review was registered with PROSPERO (CRD42016041425) and was conducted in line with the PRISMA statement. Eligibility criteria for this review included published case reports, case series and reviews that identified sequence variants or protein or functional studies from patients with HS. Sixty-two articles were identified reporting a total of 41 sequence variants – heterozygous missense (nine), splice site (nine), insertion resulting in frameshift (one), premature termination codon (19) and promoter region PSTPIP1 (three) – with 18 associated protein or functional studies. The American College of Medical Genetics and Genomics standards and guidelines on the interpretation of sequence variants were applied to each identified variant to assess evidence for pathogenicity. Twenty-three variants were assessed as likely pathogenic, 17 of uncertain significance and one benign. The large number of variants of ‘uncertain significance’ is largely due to the variable number of functional studies. Four studies used Notch as a proxy for γ-secretase function, with conclusions of nonpathogenicity based on the assumption of Notch signalling as the sole pathogenic process. The role of Notch-independent signalling mechanisms requires further research. Limitations to this study include identification of variants of Mendelian inheritance and not complex polygenic traits.
- 7 September 2017
- Published by Wiley in International Journal of Dermatology
- Vol. 57 (1) , 10-18
SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature
SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome is a rare inflammatory condition describing the combination of skin, bone, and joint manifestations that has a heterogeneous presentation. We report a case of severe SAPHO syndrome in association with hidradenitis suppurativa and pyoderma gangrenosum in a 27‐year‐old male. The patient had an initial migratory arthritis affecting the knees, ankles, metacarpophalangeal joints, proximal interphalangeal joints, wrists, shoulder, and lower back, which progressed to a persistent arthritis and swelling at the sternum, shoulders, wrists, hands, feet, and lower back. Radiographic changes were consistent with the diagnosis of SAPHO syndrome. Serum proinflammatory cytokine levels were significantly elevated and improved substantially after 3 months of therapy. Rationale for therapy in this patient was the observation that tumor necrosis alpha antagonists have been successfully used in SAPHO syndrome, and since arthropathy was so prominent in our patient, we elected to use adalimumab combined with methotrexate.
- 7 September 2017
- Published by Wiley in International Journal of Dermatology
- Vol. 57 (1) , 10-18
SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature
SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome is a rare inflammatory condition describing the combination of skin, bone, and joint manifestations that has a heterogeneous presentation. We report a case of severe SAPHO syndrome in association with hidradenitis suppurativa and pyoderma gangrenosum in a 27‐year‐old male. The patient had an initial migratory arthritis affecting the knees, ankles, metacarpophalangeal joints, proximal interphalangeal joints, wrists, shoulder, and lower back, which progressed to a persistent arthritis and swelling at the sternum, shoulders, wrists, hands, feet, and lower back. Radiographic changes were consistent with the diagnosis of SAPHO syndrome. Serum proinflammatory cytokine levels were significantly elevated and improved substantially after 3 months of therapy. Rationale for therapy in this patient was the observation that tumor necrosis alpha antagonists have been successfully used in SAPHO syndrome, and since arthropathy was so prominent in our patient, we elected to use adalimumab combined with methotrexate.
- 9 August 2017
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 59 (2) , 138-140
Hidradenitis suppurativa: A neglected disease in Indigenous Australians
We report the first case series of hidradenitis suppurativa in patients of Indigenous Australian heritage. The incidence and ethnicity of populations affected by this condition are not known. The high comorbid disease burden and socioeconomic disadvantage that is well recognised in the Indigenous Australian population poses significant challenges to therapeutic outcomes.
- 9 August 2017
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 59 (2) , 138-140
Hidradenitis suppurativa: A neglected disease in Indigenous Australians
We report the first case series of hidradenitis suppurativa in patients of Indigenous Australian heritage. The incidence and ethnicity of populations affected by this condition are not known. The high comorbid disease burden and socioeconomic disadvantage that is well recognised in the Indigenous Australian population poses significant challenges to therapeutic outcomes.
- 1 January 2017
- Vol. 46 (8) , 584-588
Hidradenitis suppurativa - Management, comorbidities and monitoring.
Hidradenitis suppurativa (HS) is a chronic inflammatory disease presenting in intertriginous areas. HS is associated with a number of disease-modifying comorbidities, including metabolic syndrome and androgen dysfunction, and smoking. This review provides a synopsis of the aetiology and diagnosis of HS, and an overview of management for this often devastating disease. The clinical course and disease severity of HS are variable among patients. HS has profound physical and psychological consequences that affect patients' quality of life. Effective treatment is now a realistic goal, but needs to be combined with treatment of the comorbidities and psyche. Evidence-based management guidelines have been established for the management of this disease. General practitioners play a pivotal role in the holistic treatment of this disease.
- 1 January 2017
- Vol. 46 (8) , 584-588
Hidradenitis suppurativa - Management, comorbidities and monitoring.
Hidradenitis suppurativa (HS) is a chronic inflammatory disease presenting in intertriginous areas. HS is associated with a number of disease-modifying comorbidities, including metabolic syndrome and androgen dysfunction, and smoking. This review provides a synopsis of the aetiology and diagnosis of HS, and an overview of management for this often devastating disease. The clinical course and disease severity of HS are variable among patients. HS has profound physical and psychological consequences that affect patients' quality of life. Effective treatment is now a realistic goal, but needs to be combined with treatment of the comorbidities and psyche. Evidence-based management guidelines have been established for the management of this disease. General practitioners play a pivotal role in the holistic treatment of this disease.
- Open Access
- 9 September 2016
- Published by Wiley in Internal Medicine Journal
- Vol. 46, 27-28
ASCIA-P74: AUSTRALIAN AUTOINFLAMMATORY DISEASES REGISTRY (AADRY): A NATIONAL APPROACH TO THE GENETIC AND IMMUNOLOGICAL EVALUATION OF PATIENTS WITH SUSPECTED AUTOINFLAMMATORY DISEASE
- 9 September 2016
- Published by Wiley in Internal Medicine Journal
- Vol. 46, 27-28
Open AccessASCIA-P74: AUSTRALIAN AUTOINFLAMMATORY DISEASES REGISTRY (AADRY): A NATIONAL APPROACH TO THE GENETIC AND IMMUNOLOGICAL EVALUATION OF PATIENTS WITH SUSPECTED AUTOINFLAMMATORY DISEASE